EGFR and non-small cell lung carcinoma: The phase 1b TATTON study enrolled patients with advanced EGFR-mutant NSCLC who progressed on a prior EGFR-TKI in order to assess the safety and tolerability of osimertinib combined with selumetinib (MEK1/2 inhibitor), savolitinib (MET inhibitor), or durvalumab (anti-PD-L1 monoclonal antibody) [98].